[Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology]. / Zweitlinientherapie des metastasierten Urothelkarzinoms : Update Immunonkologie.
Urologe A
; 59(7): 804-809, 2020 Jul.
Article
em De
| MEDLINE
| ID: mdl-32472222
ABSTRACT
The approval of the PD1 and PD-L1 (programmed cell death [ligand] 1) antibodies pembrolizumab, nivolumab, and atezolizumab has fundamentally changed the therapeutic landscape of locally advanced or metastatic urothelial carcinoma. Checkpoint inhibitors (CPI) are the standard of care in second-line treatment if not already used in first line. They replace conventional chemotherapeutics such as vinflunine, paclitaxel, or docetaxel and offer a superior toxicity profile. This article provides an overview of current second-line treatment strategies for locally advanced or metastatic urothelial carcinoma.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Neoplasias Urológicas
/
Antígeno B7-H1
/
Nivolumabe
/
Imunoterapia
Limite:
Humans
Idioma:
De
Revista:
Urologe A
Ano de publicação:
2020
Tipo de documento:
Article